康恩贝(600572.SH)：子公司氨甲环酸片获得药品注册证书

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kang En Bei Pharmaceutical Co., Ltd. to market Tranexamic Acid Tablets, which are primarily used for various bleeding conditions caused by hyperfibrinolysis [1] Group 1 - The approved specification for Tranexamic Acid Tablets is 0.25g [1] - The drug is indicated for both acute and chronic bleeding, whether localized or systemic, due to primary hyperfibrinolysis [1] - It is also used for secondary hyperfibrinolytic states caused by disseminated intravascular coagulation [1]